Welcome to the Horizon 2020 atherosclerosis research program website
Prof. Erik Stroes (AMC, Amsterdam) and Prof. Alberico Catalano (UMIL, Italy) have teamed up with Prof. Wolfgang Koenig (TUM, Munich) and prepared a successful transnational ERA-CVD research application entitled OPERATION. The OPERATION project aims to combine state-of-the-art genome-scale metabolic modelling on plasma monocytes with plasma proteomics to select a biomarker pattern correlating with arterial wall inflammation.
In this paper the LMU (Munich) and AMC (Amsterdam) groups show that blocking CD40-TRAF6 interactions by Small Molecule Inhibitors (TRAF-STOP) treatment strongly reduces atherosclerosis by preventing activation of classical monocytes, leukocyte recruitment, and macrophage activation and migration in the arterial wall. TRAF-STOPs can overcome the current limitations of long-term CD40 inhibition in atherosclerosis and have the potential to become a
The groups of AMC (the Netherlands) and REGIONH (Denmark) collaborated on elucidating the mechanisms by which remnant cholesterol particles may induce inflammatory changes. Remnant cholesterol can be readily taken up by plaque macrophages without previous oxidation of the particle, thereby promoting arterial inflammation. This reaction propagates continued influx of circulating immune cells, predominantly monocytes, into atherosclerotic lesions in both experimental models8 and patients,
With many world-leading experts already confirmed in the scientific programme, EAS 2018 Lisbon (5-8 May) is the place to come for a bench-to-bedside overview of the latest current research in the field. Be inspired by the award-winning Anitschkow Lecture, by outstanding Keynote lectures, by state-of-the-art Plenary sessions, and focussed Workshops and Advanced Clinical Seminars. EAS
In the high impact European Heart Journal, The AMC group (Bernelot Moens et al) published a European Heart Journal paper on the impact of LDL cholesterol lowering on monocyte phenotype and function in patients with familial hypercholesterolaemia not using statins due to statin-associated muscle symptoms.. This open-access article can be found here (doi:10.1093/eurheartj/ehx002). The group shows that lipid lowering
The RadboudUMC group led by Prof. Niels Riksen and Prof. Mihai Netea very recently published cutting edge results in Cell press about influencing our immune system by utilizing the “Trained Immunity” concept, key to the REPROGRAM project. Metabolic induction or trained immunity involves mevalonate pathway, Siroon Bekkering et al., Cell, January 11, 2018 Cholesterol inhibitor
In the high impact European Heart Journal, the REPROGRAM consortium published an invited review of the REPROGRAM concepts and approaches. This open-access article can be found here (doi:10.1093/eurheartj/ehx581) Main message: Chronic inflammatory diseases are the most common diseases of ageing and represent one of our major health threats. These include. most forms of cardiovascular diseases,
Agnieszka Pajak, a REPROGRAM-dedicated PhD-student working at the University Hospital Zurich (Switzerland) on Trained Immunity in rheumatoid arthritis was invited to give a talk at the Annual European Congress of Rheumatology (European League Against Rheumatism, EULAR). The following EULAR congress is planned in Amsterdam (the Netherlands) from 13 till 16 June 2018.
Renewed interest in immune cell metabolism has led to the emergence of a research field aimed at studying the importance of metabolic processes for an effective immune response. In addition to the adaptive immune system, cells of the myeloid lineage have been shown to undergo robust metabolic changes upon activation. In the Cell Metabolism paper, published by
Bonn University (Prof. Eike Latz) and Radboud University Medical Center Nijmegen (Prof. Niels Riksen and Dr. Siroon Bekkering) published a review in the journal Seminars on Immunology in which they discuss the concept of trained innate immunity in the context of a hyperlipidemic environment and atherosclerosis. According to this idea the epigenome of myeloid (progenitor) cells is presumably modified
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.